MiHA-DC vaccinatie na allogene stamceltransplantatie.
- Conditions
- Patients with AML, MDS, ALL, CML (accelerated or blast phase), CLL, MM or malignant NHL, who underwent HLA-matched allo-SCT.
- Registration Number
- NL-OMON29214
- Lead Sponsor
- Radboud University Nijmegen Medical Centre
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients positive for HLA-A2 and/or HLA-B7.
- Patients positive for HA-1, LRH-1 and/or ARHGDIB transplanted with the corresponding MiHA-negative donor.
Exclusion Criteria
- Life expectancy < 3 months.
- Severe neurological or psychiatric disease.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary study parameters are to evaluate the safety, toxicity, development of GVHD and the immunological response by appearance of MiHA-specific CD8+ T cells following vaccination with monocyte-derived donor DC electroporated with mRNA encoding hematopoietic-restricted MiHA in patients who had undergone allo-SCT with stem cells from a HLA-matched, MiHA-mismatched donor.
- Secondary Outcome Measures
Name Time Method The secondary study parameters are to evaluate the clinical effect of MiHA-DC vaccination in case of detectable minimal residual disease and mixed chimerism.